2018 AHA 儿童高级生命支持指南重点更新:抗心律失常药物在难治性室颤/无脉性室速中的应用
该更新基于国际复苏联络委员会儿科工作组2018年证据审查,聚焦儿童难治性室颤/无脉性室速的抗心律失常药物治疗。仅识别出1项儿科研究,显示利多卡因较胺碘酮显著改善自主循环恢复,但出院存活率无差异。写作组重申2015年推荐:利多卡因或胺碘酮均可用于此类患儿。
要点
- 儿童难治性室颤/无脉性室速可选用利多卡因或胺碘酮。
- 利多卡因较胺碘酮改善自主循环恢复,但出院存活率无差异。
- 证据仅来自1项儿科研究,推荐基于有限证据。
核心结论
- 对于儿童难治性室颤/无脉性室速,利多卡因或胺碘酮均可使用。
研究设计与样本
- 美国心脏协会2018年重点更新,基于国际复苏联络委员会儿科工作组2018年证据审查。
- 仅识别出1项儿科研究,比较利多卡因、胺碘酮或无抗心律失常药物。
主要发现
- 利多卡因与胺碘酮相比,自主循环恢复有统计学显著改善。
- 接受胺碘酮、利多卡因或无抗心律失常药物的患者间,出院存活率无差异。
关键数值与推荐
- 推荐:利多卡因或胺碘酮可用于儿童难治性室颤/无脉性室速。
临床怎么用
- 临床可选用利多卡因或胺碘酮处理儿童难治性室颤/无脉性室速。
- 选择药物时需权衡自主循环恢复获益与出院存活率无差异的证据。
局限性
- 仅基于1项儿科研究,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This 2018 American Heart Association focused update on pediatric advanced life support guidelines for cardiopulmonary resuscitation and emergency cardiovascular care follows the 2018 evidence review performed by the Pediatric Task Force of the International Liaison Committee on Resuscitation. It aligns with the International Liaison Committee on Resuscitation's continuous evidence review process, and updates are published when the group completes a literature review based on new published evidence. This update provides the evidence review and treatment recommendation for antiarrhythmic drug therapy in pediatric shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. As was the case in the pediatric advanced life support section of the "2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care," only 1 pediatric study was identified. This study reported a statistically significant improvement in return of spontaneous circulation when lidocaine administration was compared with amiodarone for pediatric ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, no difference in survival to hospital discharge was observed among patients who received amiodarone, lidocaine, or no antiarrhythmic medication. The writing group reaffirmed the 2015 pediatric advanced life support guideline recommendation that either lidocaine or amiodarone may be used to treat pediatric patients with shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.
引用
- Duff JP, Topjian A, Berg MD, et al. 2018 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2018. PMID: 30571264. doi:10.1161/CIR.0000000000000612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。